Andrew Arno
CIK 1472122 · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$50.6K
Companies
6
Total Filings
61
Lifetime Open-Market Net
$618.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 164,589 | $3.20 | $526.7K | $480.0K | 22 | 2026-07-06 |
| VTAK | Director | — | $0.28 | — | $0 | 3 | 2026-03-30 |
| SMSI | Director | 17,976 | $2.80 | $50.3K | $99.5K | 19 | 2026-03-10 |
| XXII | Director | 58 | $4.41 | $256 | $17.5K | 3 | 2025-11-14 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | Director | 5,000 | — | — | $21.6K | 4 | 2018-06-25 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Director | — | — | — | $0 | 1 | 2017-04-03 |
Recent Filings · Page 3 of 7
61 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-28 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +250,000 | $87.9K | EDGAR |
| 2022-08-22 | SMSI | Buy (P) | +27,500 | $64.2K | EDGAR |
| 2022-08-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +15,000 | $13.5K | EDGAR |
| 2022-08-18 | SMSI | Buy (P) | +15,000 | $35.3K | EDGAR |
| 2022-08-17 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Mixed | +160,000 | $144.1K | EDGAR |
| 2022-07-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Exer (M) | +10,000 | $0 | EDGAR |
| 2022-01-20 | SMSI | Grant (A) | +25,000 | $0 | EDGAR |
| 2021-06-28 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-18 | SMSI | Grant (A) | +25,000 | $0 | EDGAR |
| 2020-12-15 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +9,602 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.